News & Events

SkinBioTherapeutics Half Year Results

SkinBioTherapeutics Half Year Results

Manchester, UK – 14 February 2019 – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2018.

  • Successful completion of safety and irritancy human studies, even at very high doses
  • Commencement of efficacy human study with 60 subjects treated; study on track to complete during Q1 2019
  • Ongoing commercial discussions ahead of efficacy data readout
  • Loss from operations of £632k (H1 2017: £386k) based on ongoing R&D and operating expenditure
  • Cash as at 31 December 2018 £2.5m (H1 2017: £3.6m), in line with management’s expectations
  • Dr. Cath O’Neill to transition from CEO role during 2019

Martin Hunt, Chairman of SkinBioTherapeutics, said:

“The past six months has continued to be busy, as we put the scientific and manufacturing foundations in place to support SkinBiotix® through human safety studies and onto commercialisation. The next half of the financial year will be focused on progressing partnerships around the technology on the back of the human study data. We expect the next six months to be as equally busy.

“As mentioned in this statement, we are also approaching a point where the focus of the Company is changing. Consequently Cath is going to be transitioning from her role as CEO. She has played a central part in the science and the Company from the start, by discovering the technology, wrapping a company around it and leading it through the IPO and early life as a listed company. We are very grateful to her for her contribution to date as CEO. The aim now is to find someone as dedicated and passionate about the technology who will take the Company to the next stage.”

Dr. Cath O’Neill, CEO, added:

“I am very proud of everything that has been achieved by SkinBioTherapeutics in such a short time. Our ambition to enter the skin health market with a microbiome-based technology founded on a credible science, is progressing well. As a member of the Board, I am determined to find a suitable individual for the CEO role with the same passion for the science, as well as commercial acumen. Until someone is appointed, my priority is to continue to guide the Company through its first major human study and talks with potential partners.”

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For the full results statement, see

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O’Neill and Professor Andrew McBain.

SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix PLC (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit

Issued for and on behalf of SkinBioTherapeutics plc by Instinctif Partners.
For more information please contact:

back to news


Sue CharlesManaging Partner